JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $77 from $76 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $100 from $55 at Goldman Sachs
- BridgeBio Pharma’s Earnings Call Highlights Success and Challenges
- BridgeBio price target raised to $80 from $66 at Truist
- BridgeBio price target raised to $95 from $60 at TD Cowen
- BridgeBio price target raised to $81 from $73 at Oppenheimer